Currently Enrolling
If you're interested in participating or would like to learn more, please contact our study coordinator:
Karen Ekstam Smith
(319) 353-5158
VIVA-MIND:
The VIVA-MIND Study is a Phase 2 national multi-site clinical trial testing an investigational drug called Varoglutamstat (PQ912) for people who are age 50-89, and experiencing significant memory concerns, or who have already been diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer’s disease (AD). This stage of the disease, MCI through mild AD disease, is also known as early AD. The trial is designed to determine if the study drug may delay or slow the progression of the symptoms of early Alzheimer’s disease.
BenfoTeam
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease This is a randomized, double-blind, placebo-controlled 18-month clinical trial of benfotiamine in early AD.
ADNI4
The ADNI4 Study is a multi-center, non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI), and dementia (DEM). Approximately 750 participants will be newly enrolled into the ADNI4 Study, while 750 participants will be rollover participants, continuing their participation from previous ADNI studies. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across the three cohorts. Participants enrolled in the ADNI4 Study will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (amyloid and tau), and MRI scans and cerebral spinal fluid (CSF) collection for up to 5 years.
Recently Completed Studies
A4
The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the A4 Study) was a clinical trial for adults ages 65-85 who have normal thinking and memory function but who may be at risk for Alzheimer’s due to family history of the disease and elevated levels of amyloid plaque in the brain. The study aims to prevent the memory loss associated with the disease.
NIC/MIND
The purpose of the Memory Improvement Through Nicotine Dosing (MIND) study was to determine whether daily transdermal nicotine (patch) will have a positive effect on early memory impairment in participants diagnosed with Mild Cognitive Impairment (MCI).
T2 Protect AD
The T2 Protect AD Study is a national multi-site clinical trial testing an investigational drug for people with mild to moderate Alzheimer’s disease (AD). The trial is designed to determine if the study drug can protect against, or slow down, memory and thinking problems that increase as Alzheimer’s disease progresses.
FYN/CONNECT
The CONNECT study tested whether an oral, experimental drug, AZD0530 (saracatinib), will slow progression in early stage Alzheimer’s disease (AD). In its early stage after the medical diagnosis of Alzheimer’s disease, patients typically show some memory loss but a majority of daily functions are intact, requiring some reminders or help organizing the day from others in the household.
ADNI2
The purpose of ADNI2 is to examine how brain imaging and other biomarkers can be used to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease. The overall goals are increased knowledge concerning the sequence and timing of events leading to MCI and Alzheimer's disease, better methods for early detection of these conditions, and data that informs clinical trials aimed at slowing disease progression.
TCAD/NOBLE
This Phase II study evaluated the efficacy of the experimental drug T-817MA as a possible treatment for people with mild to moderate Alzheimer's disease. Participants will take tests to determine the drug's effects on memory, other aspects of cognition, and daily functioning. Physical exams, blood tests, and brain scans (MRI) will also be done.
ADNI3
The Alzheimer’s Disease Neuroimaging Initiative (ADNI), a landmark study that began in 2004, is a public-private research partnership tasked with identifying biomarkers to detect Alzheimer’s disease (AD). The study has gathered and analyzed thousands of brain scans, genetic profiles and biomarkers in blood and cerebrospinal fluid (CSF) and was designed to enable researchers to follow AD as it progresses in an individual, from various points in the disease process. ADNI3 will include 600 new participants age 55-90 and 600 rollover participants from ADNI2.